
    
      OBJECTIVES:

        -  To evaluate the safety and efficacy of imatinib mesylate in patients with resectable
           hepatic metastasis secondary to gastrointestinal stromal tumor.

      OUTLINE: This is a multicenter study.

      Patients receive oral imatinib mesylate daily. Treatment continues in the absence of disease
      progression or unacceptable toxicity.
    
  